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Variant Burkitt-type translocation, t(8;22)(q24;q11), is very rare in plasma cell myeloma. 
We report a 51-year-old male patient with plasma cell myeloma, who showed t(8;22) 
(q24;q11). He suffered from pelvic pain for two months, and showed IgG, lambda type 
of monoclonal gammopathy (5.14 g/dL; 49.9% of protein). His bone marrow examination 
showed increased plasma cells (66.9% of all nucleated cells). Plasma cells (74.9% of all 
nucleated cells) and monoclonal spike (3.38 g/dL; 42.2%) persisted after three cycles of 
thalidomide and dexamethasone. Cytogenetic analysis showed complex chromosomal 
abnormalities: 44,XY,-1,t(2;5)(q33;q13),add(8)(q24.1),t(8;22)(q24.1;q11.2),add(10) (p15), 
der(11)t(1;11)(q21;p11.2),del(12)(p11.2p13),-13,-14,add(14)(q32),der(15)t(1;15)(p2
2;p11.2),-16,add(17)(q11.2),+21,+1-3mar[cp6]/46,XY[19]. To the best of our knowl-
edge, this is the first report on plasma cell myeloma with a variant Burkitt-type 
t(8;22)(q24;q11) in the Korean patient. A review of 11 such cases in the literature, includ-
ing the present case, implicated that plasma cell myeloma with t(8;22)(q24;q11) might 
be related to advanced stage and poor prognosis.
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INTRODUCTION
Plasma cell myeloma is a B-cell clonal malignancy that 
is characterized by the accumulation of terminally differ-
entiated plasma cells, which features monoclonal gammop-
athy, hypercalcemia, renal failure, anemia, and osteolytic 
bone lesions. Plasma cell myeloma accounts for 10% of hema-
tological neoplasms, and it has a median survival of 2-3 
years [1, 2]. Abnormal karyotypes are observed in about 
30-50% of plasma cell myelomas, and are usually associated 
with aggressive disease courses. 
The t(8;14)(q24;q32) is classically related to Burkitt’s lym-
phoma, and has been also seen in small noncleaved cell 
lymphoma, immunoblastic lymphoma, and, less frequently, 
in plasma cell myeloma [3]. The c-myc gene at 8q24 is juxta-
posed to the immunoglobulin heavy chain (IgH) gene at 
14q32 and dysregulated. Variant Burkitt-type translocations, 
t(2;8)(p12;q24) or t(8;22)(q24;q11), are also specifically ob-
served in Burkitt’s lymphoma. These translocations, t(2;8) 
(p12;q24) and t(8;22)(q24;q11), involve light chain genes, 
Igκ  and  Igλ, respectively [4]. 
We present a variant Burkitt-type translocation, t(8;22) 
(q24;q11), in a patient with resistant plasma cell myeloma. 
To the best of our knowledge, this is the first report on 
the variant Burkitt-type translocation, t(8;22)(q24;q11), re-
lated to plasma cell myeloma in Korea. We also reviewed 
11 such cases, including the present case, to explore the 
clinical relevance of variant Burkitt-type translocation, 
t(8;22)(q24;q11), in plasma cell myeloma.
CASE REPORT
In August 2010, a 51-year-old-male presented with right 
pelvic pain, occipital headache, weight loss, and weakness, 
which lasted for two months. He had visited a local hospital, 
and was referred to our hospital for further work-up under 
the suspicion of a hematologic malignancy. On physical ex-
amination, neither organomegaly nor lymphadenopathy was 
noted. His complete blood counts were: white blood cells, 
6.3×10
9/L; hemoglobin, 8.9 g/dL; platelets, 233×10
9/L. The 
other laboratory findings were: total protein, 10.4 g/dL; albu-
min 2.5 g/dL; calcium, 8.6 mg/dL; blood urea nitrogen, 22.6 
mg/dL; creatinine, 1.4 mg/dL; beta-2-microcroglobulin, 6.4 
mg/L. Serum protein electrophoresis showed a monoclonal Korean J Hematol 2011;46:135-8.
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Fig. 2. Karyogram of follow-up 
bone marrow cells by Giemsa 
banding technique. 44,XY,-1,t(2;5) 
(q33;q13),add(8)(q24.1),t(8;22)(q
24.1;q11.2),add(10)(p15),der(11) 
t(1;11)(q21;p11.2),del(12)(p11.2
p13),-13,-14,add(14)(q32),der(15
)t(1;15)(p22;p11.2),-16,add(17)(
q11.2),+21,+1-3mar[cp6].
Fig. 1. Bone marrow aspiration smear showing increased plasma cells 
(Wright-Giemsa stain, ×1,000).
spike (5.14 g/dL; 49.9% of protein), which was confirmed 
as IgG, lambda type of monoclonal gammopathy by serum 
immunofixation. Radiographically, multiple osteolytic le-
sions were detected in right pelvic bone, spines, and skull.
Plasma cells were increased on the bone marrow aspirate 
smear (66.9% of all nucleated cells), and showed dispersed 
nuclear chromatin, high nuclear/cytoplasmic ratio, and often 
prominent nucleoli (Fig. 1). The patient was diagnosed as 
having plasma cell myeloma. Flow cytometric immuno-
phenotyping and cytogenetic analysis could not be performed 
at diagnosis, because the bone marrow study was performed 
at the previous hospital.
After three cycles of thalidomide and dexamethasone, 
monoclonal spike (3.38 g/dL; 42.2%) was persistent, and 
plasma cells were counted up to 74.9% of all nucleated cells 
on the follow-up bone marrow aspirate smear. Flow cyto-
metric immunophenotyping demonstrated an expanded pop-
ulation of abnormal plasma cells with CD19 negativity and 
positivity for the followings: CD38, 60%; CD138, 58%; CD56, 
60%. Flow cytometric immunotyping for CD20, CD10 and 
light chain were not performed. Cytogenetic analysis showed 
a complex karyotype: 44,XY,-1,t(2;5)(q33;q13),add(8)(q24.1), 
t(8;22)(q24.1;q11.2),add(10)(p15),der(11)t(1;11)(q21;p11.2),
del(12)(p11.2p13),-13,-14,add(14)(q32),der(15)t(1;15)(p22;p
11.2),-16,add(17)(q11.2),+21,+1-3mar[cp6]/46,XY[19] (Fig. 2) 
[5]. Under the diagnosis of stable disease, he has received 
1 cycle of bortezomib and dexamethasone, and has been 
clinically stable. 
 DISCUSSION
C o m p l e x  k a r y o t y p e s  a r e  s e e n  i n  3 0  t o  5 0 %  o f  p l a s m a  
cell myeloma. Abnormal karyotypes are more often seen 
in advanced diseases, and are associated with increasing pro-
liferative activity of malignant cells and poor outcome [1, 
6]. Poor-risk genetic abnormalities, such as the presence 
of t(14;16), t(14;20), del(13), t(4;14), and del(17p), are asso-
ciated with significantly shorter event-free survival, overall 
survival, and duration of response [6]. 
In this report, we have identified t(8;22)(q24;q11), a variant 
of t(8;14), in a patient with plasma cell myeloma. The break-
points at 8q24 are localized within 300 kb downstream of 
the  c-myc  gene, and c-myc  rearrangement, especially 
through t(8;14), is a major event in the oncogenesis of plasma-
cytomas [7]. As a result of t(8;14) or its variants, the oncogene Korean J Hematol 2011;46:135-8.
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Table 1. Summary of 11 cases with plasma cell myeloma and t(8;22)(q24;q11).
No.
Sex/
Age (y)
Karyotype M-protein Stage
a) BM-PC 
(%)
Survival 
(m)
b) Reference
1 M/67 42,X,-Y,der(1)t(1;1)(p13.3;q12),+3,der(3)t(3;14)(q25;q23),t(8;22)(q24.1;
q11),i(9)(q10),-11,-13,-14,-15,der(16)t(15;16)(q11,q24),der(19)t(13;19)
(q12.3;p13.3)[12]/84,idem×2[4]
BJP IIIB 93 8 [10] Taniwaki 
et al. 1994
2 M/69 49,XY,+5,t(8;22)(q24;q11),+11,+19 IgG III 60-100 120 [8] Solé et al. 
1994
3 M/72 49,XY,+Y,+i(1)(q10),t(1;15)(p36;q26),-4,t(8;22)(q24;q11),+9,-13,add(16)
(q24),+19,+21[15]
IgA NR 65 NR [11] Sawyer 
et al. 1995
4 M/57 51,XY,+5, t(8;22)(q24;q11),+9,+11,+15,+19[20] IgG IIIB 90 11
c) [12] Look 
et al. 1995
5 M/66 50,XY,del(2)(q34),+5,del(6)(q21),+del(6)(q21),t(8;22)(q24;q12),+9,+11, 
-13,+15, der(16)t(1;16)(q10;p10),-18+19[3]
IgG IIIB 48 36 [13] 
Mugneret 
et al. 1995
6 M/73 82,X,der(Y)t(1;Y)(q11-qter;q12),+1,+2,+3,+3, add(4)(p16),+5,+5, 
+del(6)(q15q24),+del(6)(q15q24),del(6)(q22),+7,+7,+8,+8, 
t(8;22)(q24;q11),+der(9;14)(q10;q10),+der(9;14) (q10;q10),+11,+11,
+del(12)(q24),+del(12)(q24),+dup(13)(q14;q33),+15,+15,+16, 
+der(16),t(1;16)(q10;p10),+17,+17,+18,+18,+19,+19,+20,+20,+21, 
+21,+22,+22[21]
IgA IIA 37 36 [13] 
Mugneret 
et al. 1995
7 M/41 50,XY,t[del(1)(p21p32);3](p35;p13),-6,+add(6)(q21), +add(6)(q21), 
del(7)(q21q31),del(7)(q21q31),+del(7)(q21q31),add(8)(p11),+8+der(8)
(8p21-cent-q24::22q11),t(11;14)(q13;q32),der(12)(12pter-cent-12q24::
12q14-12q24),del(13)(q13q21),+15,-16,+der(16)t(1;16)(q10;p10),
add(19)(p13),-20,+21,+der(22)t(8;22)(q24;q11)[5]
IgD IIIB 23 24 [13] 
Mugneret 
et al. 1995
8 M/NR 49,XY,+5,t(8;22)(q24;q11),+11,+19[10] NR NR NR NR [14] Calasanz 
et al. 1997
9 F/76 53,XX,der(1)add(1)(p11)dup(1)(q12q32),+3,+5,t(8;22)(q24;q11),+9,
add(10)(p13),+11,+15,+add(19)(q13),+21[10]/54,XX, add(1)(p11), 
+i(1)(q10),+3,+5,t(8;22)(q24;q11),+9,add(10)(p13),+11,+15, 
+add(19)(q13),+21[5]
IgG IIIA 72 25 [4] Yamamoto 
et al. 1998
10 F/68 52,XX,+add(1)(p11),del(1)(p13p21),add(4)(p11),+7?der(8)(p11.2)t(8;22)
(q24;q11.2),+add(9)(q22),-13,+15,-16,+18,-21,?der(22)t(8;22),+mar1,
+mar2,+mar3,+mar4[3]/50,sl,-3,-7[1],53,sl,-10,+2mar[1]/52,sl,add(3)
(q11.2),-7,+12[1]/51,sl,+4,-add(4),-15,del(16)(q?)[1]/51,sl,-add(4),
+add(4)(p11),-14,add(16)(q13)[1]
IgA NR 77.6 NR [15] Sugiyama 
et al. 2009
11 M/51 44,XY,-1,t(2;5)(q33;q13),add(8)(q24.1),t(8;22)(q24.1;q11.2),add(10)(p15),
der(11)t(1;11)(q21;p11.2),del(12)(p11.2p13),-13,-14,add(14)(q32),
der(15)t(1;15)(p22;p11.2),-16,add(17)(q11.2),+21,+1-3mar[cp6]
IgG IIIA 66.9 8
c) Present case 
2011
a)according to the Durie and Salmon staging system, 
b)survival duration from diagnosis, 
c)alive.
Except the present case, the others show the karyotype at initial diagnosis.
Abbreviations: y, years; m, months; BJP, Bence Jones protein; F, female; M, male; NR, not reported; BM-PC, plasma cells in bone marrow.
c-myc  is juxtaposed into the immunoglobulin gene locus 
[8]. C-myc rearrangements were observed significantly more 
often in patients with β2-microglobulin levels above 3 mg/L 
[9].
The variant Burkitt-type translocation, t(8;22)(q24;q11), 
has been reported in a limited number of cases, and only 
18 such cases are found in the literature [4, 8, 10-15]. Among 
these 18 cases, eight cases were reported only with the results 
of fluorescence in situ hybridization (FISH), without detailed 
cytogenetic and clinical information [9]. The other 11 cases 
with variant Burkitt-type t(8;22), including our case, are 
summarized in Table 1. Only two of them were reported 
to be alive, and all the cases with t(8;22)(q24;q11) had com-
plex chromosomal abnormalities. 
The presence of an abnormal karyotype is known to be 
related to a worse prognosis in plasma cell myeloma [4]. 
Because all the reported cases with variant Burkitt-type 
t(8;22) concurrently showed complex karyotypic abnormal-
ities, it is uncertain whether the variant Burkitt-type t(8;22) 
itself has prognostic or clinicopathologic implications or not. 
Further accumulation of cases with clinical details would 
be necessary to answer this question. In the present case, 
the initial chromosome study was not available, and the 
follow-up study was done within 84 days. Considering the Korean J Hematol 2011;46:135-8.
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other reported cases, we assume that the complex karyotype, 
including t(8;22), had been present since the initial diagnosis. 
In summary, we report a variant Burkitt-type trans-
location, t(8;22)(q24;q11), in a patient with resistant plasma 
cell myeloma. A review of the literature implicated that 
t(8;22)(q24;q11) might be observed in plasma cell myeloma 
as a part of complex chromosomal abnormalities rather than 
a solitary cytogenetic abnormality. Consequently, plasma cell 
myeloma with t(8;22)(q24;q11) might be related to advanced 
stage and poor prognosis. Further accumulation of such cases 
is needed to delineate the clinical relevance of t(8;22) 
(q24;q11) in plasma cell myeloma.
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